Xeris Biopharma Holdings Ratios and Metrics

Market cap in millions EUR. Fiscal year is January - December.

Millions EUR. Fiscal year is Jan - Dec.

Fiscal Year	Current	FY 2024	FY 2023	FY 2022	FY 2021	FY 2020	2019 - 2016
Period Ending	Dec '25 Dec 2, 2025	Dec '24 Dec 31, 2024	Dec '23 Dec 31, 2023	Dec '22 Dec 31, 2022	Dec '21 Dec 31, 2021	Dec '20 Dec 31, 2020	2019 - 2016
Market Capitalization	929	488	294	169	321	-	Upgrade
Market Cap Growth	119.10%	66.23%	73.53%	-47.33%	-	-	Upgrade
Enterprise Value	1,071	683	440	211	317	-	Upgrade
Last Close Price	5.69	3.23	2.10	1.15	2.20	-	Upgrade
PS Ratio	4.09	2.49	1.98	1.64	7.37	-	Upgrade
PB Ratio	-1265.30	-17.07	-47.86	4.00	3.84	-	Upgrade
EV/Sales Ratio	4.68	3.48	2.97	2.05	7.26	-	Upgrade
Debt / Equity Ratio	-299.25	-9.17	-33.79	4.38	0.93	2.58	Upgrade
Asset Turnover	0.77	0.63	0.49	0.34	0.21	0.15	Upgrade
Inventory Turnover	0.73	0.85	0.90	1.06	1.01	1.77	Upgrade
Quick Ratio	1.25	1.12	1.17	2.08	1.52	4.99	Upgrade
Current Ratio	1.93	1.67	1.64	2.54	1.80	5.40	Upgrade
Return on Equity (ROE)	-	-	-324.20%	-134.83%	-190.28%	-378.20%	Upgrade
Return on Assets (ROA)	2.88%	-5.33%	-8.25%	-15.78%	-28.45%	-38.02%	Upgrade
Return on Capital (ROIC)	3.98%	-7.42%	-11.81%	-24.01%	-43.37%	-52.67%	Upgrade
Return on Capital Employed (ROCE)	6.30%	-12.40%	-19.40%	-30.20%	-46.80%	-62.30%	Upgrade
Earnings Yield	-1.44%	-10.85%	-19.18%	-52.34%	-33.59%	-	Upgrade
FCF Yield	0.92%	-7.49%	-15.18%	-57.18%	-26.44%	-	Upgrade
Buyback Yield / Dilution	-8.48%	-6.61%	-1.51%	-71.62%	-85.32%	-63.32%	Upgrade

Source: S&P Capital IQ. Standard template. Financial Sources.